[DISCLOSURE] ATGen (182400) said on Oct. 14 that it has signed a contract worth 142.9 billion won (US$125.4 million) with Kazakhstan’s DCT Biogen to supply its NK Vue Kit, an in-vitro diagnostic test.

The deal amounts to 5688.42 percent of the firm’s revenue in 2015 and expires in 2032.

By Jung Min-kyung ()